Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.36 |
| ▸ | TUBB | P07437 | 2/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9549445 | 0.82 | CA2 (0.38) | CA2CA4TUBB1PTGS2 | |
| SCHEMBL5704414 | 0.76 | CA2 (0.39) | CA2CA4TUBB1TSHRAPOBEC3A | |
| SCHEMBL27988498 | 0.74 | ACHE (0.46) | MAPTTUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL9678358 | 0.73 | POLB (0.46) | POLBL3MBTL1MAPTNPSR1PRKDC | |
| SCHEMBL1729022 | 0.72 | MAPT (0.48) | POLBL3MBTL1MAPTNPSR1CA2 | |
| SCHEMBL24572813 | 0.72 | MAPT (0.48) | POLBL3MBTL1MAPTNPSR1PRKDC | |
| SCHEMBL9804695 | 0.71 | CA2 (0.42) | POLBL3MBTL1MAPTNPSR1CA2 | |
| SCHEMBL6078582 | 0.71 | NPSR1 (0.34) | POLBL3MBTL1MAPTNPSR1TUBB1 | |
| SCHEMBL1094358 | 0.70 | POLB (0.37) | POLBL3MBTL1MAPTNPSR1PRKDC | |
| SCHEMBL624239 | 0.69 | ALOX5AP (0.46) | MAPTTUBB1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | POLB 1429/4885L3MBTL1 3327/4885MAPT 4490/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | POLB 1429/4885L3MBTL1 3327/4885MAPT 4490/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | POLB 1331/4885L3MBTL1 1272/4885MAPT 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.